Drug Trial Radar · NCT06840769
A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
50
Actual
Start
Jun 17, 2023
Primary completion
Oct 18, 2023
Study completion Oct 23, 2023
Sponsor
- Lead sponsor
- Helsinn Healthcare SAIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial will include two parts, i.e., Part A and Part B. The goal of the Part A is to define the shortest safe and tolerable duration of an intravenous injection of Fosnetupitant 235 mg solution among 4 durations tested in male and female adult healthy volunteers. In study part A, researchers will compare Fosnetupitant 235 mg solution to Akynzeo® solution. The duration determined in Part A will be investigated in study Part B. The Part B of the study was not performed.
Conditions
- Healthy Volunteers
Interventions
Fosnetupitant 235 mg solutionDrug
Fosnetupitant free base 235 mg (corresponding to 260 mg of the chloride hydrochloride salt) in 20 mL ready to use injectable solution for intravenous administration
Akynzeo solutionDrug
235 mg fosnetupitant (corresponding to 260 mg of the chloride hydrochloride salt) / 0.25 mg palonosetron in 20 mL injectable solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study Part A: Number of Treatment-emergent Adverse EventsTime frame: From screening visit (day of informed consent signature) up to 24 h after the investigational medicinal product administration (a maximum of 21 days)
- Study Part A: Number of Subjects With Treatment-emergent Adverse EventsTime frame: From screening visit (day of informed consent signature) up to 24 h after the investigational medicinal product administration (a maximum of 21 days)
- Study Part A: Type of Treatment-emergent Adverse EventsTime frame: From screening visit (day of informed consent signature) up to 24 h after the investigational medicinal product administration (a maximum of 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CROSS Research S.A.
Arzo, Canton Ticino, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.